

**Louisiana Medicaid
Beremagene Geperpavec-svdt (Vyjuvek™)**

The *Louisiana Uniform Prescription Drug Prior Authorization Form* should be utilized to request clinical authorization for beremagene geperpavec-svdt (Vyjuvek™).

Additional Point-of-Sale edits may apply.

By submitting the authorization request, the prescriber attests to the conditions available [HERE](#).

Approval Criteria for Initiation of Therapy

- ~~The recipient is 6 months of age on date of the request; AND~~
- The recipient has a diagnosis of dystrophic epidermolysis bullosa confirmed by genetic test results showing mutations in the collagen type VII alpha 1 chain (COL7A1) gene; **AND**
- The medication is prescribed by, or the request states that this medication is being prescribed in consultation with, a geneticist or dermatologist; **AND**
- The following is true and is **stated on the request** - The recipient does not have current evidence or history of squamous cell carcinoma in the area that will undergo treatment.

Approval Criteria for Continuation of Therapy

- The prescriber **states on the request** that the recipient is established on the medication with evidence of a positive response to therapy.

Duration of approval for initiation and continuation of therapy: 6 months

References

Bruckner AL and Murrell DF. Diagnosis of epidermolysis bullosa. In: UpToDate. Shefner JM (Ed), UpToDate, Waltham, MA.

Gurevich I, Agarwal P, Zhang P, Dolorito JA, Oliver S, Liu H, Reitze N, Sarma N, Bagci IS, Sridhar K, Kakarla V, Yenamandra VK, O'Malley M, Prisco M, Tufa SF, Keene DR, South AP, Krishnan SM, Marinkovich MP. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. *Nat Med.* 2022 Apr;28(4):780-788. doi: 10.1038/s41591-022-01737-y. Epub 2022 Mar 28. PMID: 35347281; PMCID: PMC9018416.

Vyjuvek (beremagene geperpavec-svdt) [package insert]. Pittsburgh, PA: Krystal Biotech, Inc; May 2023. <https://www.krystallabel.com/pdf/vyjuvek-us-pi.pdf>

Revision / Date	Implementation Date
Policy created / July 2023	January 2024
Formatting changes / March 2024	July 2024
<u>Removed age limitation / September 2025</u>	<u>April 2026</u>